Economic evaluation of critically ill adult CAR-T cell recipients-analysis from a healthcare payer perspective.

ABSTRACT:

Background

CAR-T cell (chimeric antigen receptor T) therapy is now part of standard of care treatment of B‑cell lineage malignancies. Although it is an effective treatment, it comes along with adverse side effects and toxicities that may require intensive care therapy. The costs related to critical care therapy in critically ill patients after CAR‑T administration have not been evaluated.

Patients and methods

Retrospective analysis of all patients who had received CAR‑T therapy and were admitted to the intensive care unit (ICU) of a tertiary care university medical centre in Germany between 1 January 2019 and 31 December 2022. Cause of admission and ICU therapy as well as treatment and total hospitals costs were evaluated.

Results

Thirty patients with a history of CAR

SUBMITTER: Roedl K 

PROVIDER: S-EPMC12708791 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature